wisp metabolic support & glp 1 boost capsules GLP-1 Supplement WELL's Subsidiary Wisp Launches Comprehensive
Description
Therapeutic options for the management of postprandial glucose in patients with type 2 diabetes on basal insulin
Note: animal studies indicate that high doses of DPP-4 inhibitors & GLP-1 agonists cause expansion of cells of the pancreatic ductal glands and can cause premalignant pancreatic intraepithelial lesions (PanIN) that have the potential to progress to pancreatic adenocarcinoma
12 February 2026
[DOI] [PubMed] [Google Scholar] 121.Sund N.J., Vatamaniuk M.Z., Casey M., Ang S.L., Magnuson M.A., Stoffers D.A
doi: 10.3389/fendo.2021.721198 23 CalsolaroVEdisonP
What do you hope happens next
